Eric

it's actually pretty deep. So it wasn't just that their gray hair went away, but also the fact that at the organ level, they had, for example, their glucose regulation turned back to normal. Many of their organs show young look rather than having all the things that you would associate with a very old organism. So it looks great.

it's actually pretty deep. So it wasn't just that their gray hair went away, but also the fact that at the organ level, they had, for example, their glucose regulation turned back to normal. Many of their organs show young look rather than having all the things that you would associate with a very old organism. So it looks great.

You say, wow, couldn't we just all take these Yamanaka factors and we would just get young? The problem is that when they were doing this, and this is now in multiple species, tumors would develop. And that's because when you turn back these cells into younger cells, you also are potentiating the risk of cancer.

You say, wow, couldn't we just all take these Yamanaka factors and we would just get young? The problem is that when they were doing this, and this is now in multiple species, tumors would develop. And that's because when you turn back these cells into younger cells, you also are potentiating the risk of cancer.

You say, wow, couldn't we just all take these Yamanaka factors and we would just get young? The problem is that when they were doing this, and this is now in multiple species, tumors would develop. And that's because when you turn back these cells into younger cells, you also are potentiating the risk of cancer.

And this, Mel, is the problem with many of these anti-aging body-wide interventions, is they introduce new risk particularly cancer, because there's a very close overlap between the hallmarks of aging and the hallmarks of cancer.

And this, Mel, is the problem with many of these anti-aging body-wide interventions, is they introduce new risk particularly cancer, because there's a very close overlap between the hallmarks of aging and the hallmarks of cancer.

And this, Mel, is the problem with many of these anti-aging body-wide interventions, is they introduce new risk particularly cancer, because there's a very close overlap between the hallmarks of aging and the hallmarks of cancer.

Yeah, so in the case that we're just talking about, the fancy term for it is partial epigenetic reprogramming. It sounds pretty big, right?

Yeah, so in the case that we're just talking about, the fancy term for it is partial epigenetic reprogramming. It sounds pretty big, right?

Yeah, so in the case that we're just talking about, the fancy term for it is partial epigenetic reprogramming. It sounds pretty big, right?

Yeah, yeah. But the whole idea is that when you make cells younger, a group of these cells to just take off, develop a clone of cancer, and then just spread. So the problem is that when you're trying to re-rig the body's aging process, you introduce new problems.

Yeah, yeah. But the whole idea is that when you make cells younger, a group of these cells to just take off, develop a clone of cancer, and then just spread. So the problem is that when you're trying to re-rig the body's aging process, you introduce new problems.

Yeah, yeah. But the whole idea is that when you make cells younger, a group of these cells to just take off, develop a clone of cancer, and then just spread. So the problem is that when you're trying to re-rig the body's aging process, you introduce new problems.

Exactly right.

Exactly right.

Exactly right.

Yeah, so I think where we're headed is that each of us will have, without added costs or very nominal costs, we will have all our data. It's assembled. It's analyzed by what we call multimodal AI, generative AI, and it'll tell us, This is your risk. This is what you need to be on the lookout for. And you're going to do these things.

Yeah, so I think where we're headed is that each of us will have, without added costs or very nominal costs, we will have all our data. It's assembled. It's analyzed by what we call multimodal AI, generative AI, and it'll tell us, This is your risk. This is what you need to be on the lookout for. And you're going to do these things.

Yeah, so I think where we're headed is that each of us will have, without added costs or very nominal costs, we will have all our data. It's assembled. It's analyzed by what we call multimodal AI, generative AI, and it'll tell us, This is your risk. This is what you need to be on the lookout for. And you're going to do these things.